Intellia Therapeutics announces publication of NTLA-2002 data in NEJM

Intellia Therapeutics announced that interim results from the Phase 1 portion of the Phase 1/2 study of NTLA-2002 were published online in the New England Journal of Medicine. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema, a rare genetic condition that leads to potentially life-threatening swelling attacks. “Despite currently available treatments, people living with hereditary angioedema continue to face frequent anxiety about their next swelling attack. The interim NTLA-2002 clinical data published suggest that a single dose of NTLA-2002 may eliminate angioedema attacks for people suffering from hereditary angioedema,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We are highly encouraged by these data and look forward to presenting extended follow-up from the Phase 1 and results from the Phase 2 portion later this year. Additionally, we remain on track to initiate a global pivotal study for NTLA-2002 in the second half of 2024, subject to regulatory feedback. This marks the second consecutive Intellia in vivo CRISPR-based program to have its initial clinical data published in the New England Journal of Medicine, further supporting the immense potential impact our proprietary gene editing platform could have on the future of human health.”